STORM Therapeutics
STORM is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases.
The biotech company’s expertise in RNA modifying enzymes (RME) has led to discoveries of novel small-molecule drugs that reprogram cells with precision through RNA biology to treat cancer, inflammation, viruses and diseases of the central nervous system (CNS).
STORM’s first-in-class lead product STC-15 became the first RNA-modifying enzyme inhibitor to enter human clinical development in a Phase 1 study of patients with advanced solid tumours.
STORM investors include M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences, Cambridge Innovation Capital Limited, IP Group plc, UTokyo Innovation Platform Co., Ltd. and the Fast Track Initiative (FTI).
